In his State of the Union address, President Trump called on Congress to “do more” to lower drug costs in the United States. Already, the U.S. Department of Health and Human Services (HHS) has proposed piloting an International Pricing Index payment model, tying costs for drugs under Medicare Part…

Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced therapeutic modalities and prospective cures for diseases which previously had no comparable treatments enter the market. Yet the departure from more traditional…

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. Investors’ eagerness to support new modalities enabled more than 50 biotech IPOs, but with much less mature clinical development progress than traditionally demonstrated…

Biotech startups come in all shapes, sizes and approaches but have one thing in common: the drive to develop technology that will address a high unmet need and improve patients’ lives.  Nancy Thornberry, the current CEO of Kallyope Inc., didn’t always work for startups, but she has spent a…

Dr. Aoife Brennan has always faced challenges head-on. A trained endocrinologist, she could have remained in her native country, Ireland, and led a fulfilling life as a medical doctor. Instead she embarked on a journey that eventually led to her current position as CEO of Synlogic. Brennan will be…

New medicines often progress from idea to regulatory approval through collaborative licensing agreements or acquisition.  Deal-making has become one of the most critical skills for a biotech’s leadership team in developing products to improve patients’ lives.  On February 10 BIO will…

The past year has been a transformative one for the life sciences. Despite being faced with uncertainties around cost and pricing, pressure from an Administration threatening price controls and facing a new Congress next year, the industry continued to move forward on the innovation front. With…

When pop star Demi Lovato experienced an apparent opioid-related overdose last summer, reports stated that she was saved by a medication called NARCAN® Nasal Spray — the first FDA-approved nasal form of naloxone, an opioid antagonist. The company that developed NARCAN® Nasal Spray is Opiant…